Abstract
To the Editor: Mohs micrographic surgery (MMS) is indicated for the treatment of high-risk basal cell carcinoma (BCC) based on superior long-term outcomes compared to wide local excision (WLE).1,2 Factors that may predict poor outcomes include tumor diameter of ≥2 cm, head and neck location, deep invasion, recurrence, aggressive histologic subtype, and perineural invasion.3,4 The American Joint Committee on Cancer (AJCC, 8th edition) and the Brigham and Women Hospital (BWH) staging systems have incorporated some of these parameters to risk-stratify BCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
